Sprout Social reported Q3 2026 revenue of $125.1 million, up 8% year-over-year, with non-GAAP operating income doubling to $26.3 million. The company saw an 18% increase in subscription revenue from large customers and initiated a $50 million stock buyback program. It aims for GAAP profitability starting Q4 2026 and raised its non-GAAP operating margin outlook to 18%. This signals strong financial health and growth focus on larger clients.
Sprout Social's third quarter 2026 revenue reached $125.1 million, showing an 8% year-over-year increase alongside a doubling of non-GAAP operating income to $26.3 million. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 03:41 WIB: out of 150 priced US tech stocks, 94 rose and 53 fell. Notable movers include CIFR at USD 8.07 with a 17.64% gain and nearly balanced Pluang order activity, CORZ at USD 14.15 up 13.15% with full buy-side order activity, and IT at USD 205.93 down 12.55% with a 60% buy order activity.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
